Enhanced growth inhibition of metastatic lung tumors by intravenous injection of ATRA-cationic liposome/IL-12 pDNA complexes in mice

Cancer Gene Therapy

Volumn 17, Issue 7, 2010, Pages 512-522

  Charoensit, P ^a   Kawakami, S ^a   Higuchi, Y ^a   Yamashita, F ^a   Hashida, M ^a,b  

^a KYOTO UNIVERSITY   (Japan)

^b KYOTO UNIVERSITY   (Japan)

Author keywords

All trans retinoic acid; Apoptosis; Cationic liposome pDNA complexes; IL 12; Lung metastatic; TNF receptor 1

Indexed keywords

ALANINE AMINOTRANSFERASE; ANTINEOPLASTIC AGENT; ASPARTATE AMINOTRANSFERASE; INTERLEUKIN 12; LUCIFERASE; MESSENGER RNA; RETINOIC ACID CATIONIC LIPOSOME INTERLEUKIN 12 PLASMID DNA COMPLEX; TUMOR NECROSIS FACTOR RECEPTOR 1; UNCLASSIFIED DRUG; DNA; LIPOSOME;

ANIMAL MODEL; ANTINEOPLASTIC ACTIVITY; ARTICLE; BLOOD LEVEL; CONTROLLED STUDY; DRUG EFFICACY; GENE EXPRESSION; GROWTH INHIBITION; LUNG TUMOR; MALE; METASTASIS; MOUSE; NONHUMAN; PRIORITY JOURNAL; ANIMAL; DISEASE MODEL; GENETICS; HUMAN; INTRAVENOUS DRUG ADMINISTRATION; LUNG NEOPLASMS; METABOLISM; PATHOLOGY;

ANIMALS; DISEASE MODELS, ANIMAL; DNA; HUMANS; INJECTIONS, INTRAVENOUS; INTERLEUKIN-12; LIPOSOMES; LUNG NEOPLASMS; MALE; MICE;

ATRA; MUS;

EID: 77953704558     PISSN: 09291903     EISSN: 14765500     Source Type: Journal    
DOI: 10.1038/cgt.2010.12     Document Type: Article

References (41)

1. Colombo MP, Trinchieri G. Interleukin-12 in anti-tumor immunity and immunotherapy. Cytokine Growth Factor Rev 2002; 13: 155-168.
2. Dow SW, Elmslie RE, Fradkin LG, Liggitt DH, Heath TD, Willson AP et al. Intravenous cytokine gene delivery by lipid-DNA complexes controls the growth of established lung metastases. Hum Gene Ther 1999; 10: 2961-2972.
3. Car BD, Eng VM, Lipman JM, Anderson TD. The toxicology of interleukin-12: a review. Toxicol Pathol 1999; 27: 58-63.
4. Krieg AM, Yi AK, Matson S, Waldschmidt TJ, Bishop GA, Teasdale R et al. CpG motifs in bacterial DNA trigger direct B-cell activation. Nature 1995; 374: 546-549.
5. Loisel S, Le Gall C, Doucet L, Ferec C, Floch V. Contribution of plasmid DNA to hepatotoxicity after systemic administration of lipoplexes. Hum Gene Ther 2001; 12: 685-696.
6. Sakurai F, Terada T, Yasuda K, Yamashita F, Takakura Y, Hashida M. The role of tissue macrophages in the induction of proinflammatory cytokine production following intravenous injection of lipoplexes. Gene Therapy 2002; 9: 1120-1126.
7. Kawakami S, Ito Y, Charoensit P, Yamashita F, Hashida M. Evaluation of proinflammatory cytokine production induced by linear and branched polyethylenimine/plasmid DNA complexes in mice. J Pharmacol Exp Ther 2006; 317: 1382-1390.
8. Ito Y, Kawakami S, Charoensit P, Higuchi Y, Hashida M. Evaluation of proinflammatory cytokine production and liver injury induced by plasmid DNA/cationic liposome complexes with various mixing ratios in mice. Eur J Pharm Biopharm 2009; 71: 303-309.
9. Janat-Amsbury MM, Yockman JW, Anderson ML, Kieback DG, Kim SW. Combination of local, non-viral IL12 gene therapy and systemic paclitaxel chemotherapy in a syngeneic ID8 mouse model for human ovarian cancer. Anticancer Res 2006; 26: 3223-3228.
10. Zhu S, Waguespack M, Barker SA, Li S. Doxorubicin directs the accumulation of interleukin-12-induced IFNg into tumors for enhancing STAT1 dependent antitumor effect. Clin Cancer Res 2007; 13: 4252-4260.
11. Rowinsky EK, Cazenave LA, Donehower RC. Taxol: a novel investigational antimicrotubule agent. J Natl Cancer Inst 1990; 82: 1247-1259.
12. Denis R, Vincent D, Jerome Q, Florence ML, JeanPierre D, Philippe R et al. Preclinical toxicity, toxicokinetics, and antitumoral efficacy studies of DTS-201, a tumor-selective peptidic prodrug of doxorubicin. Clin Cancer Res 2008; 14: 1258-1265.
13. Strickland S, Mahdavi V. The induction of differentiation in teratocarcinoma stem cells by retinoic acid. Cell 1978; 15: 393-403.
14. Lotan R, Francis GE, Freeman CS, Waxman S. Differentiation therapy. Cancer Res 1990; 50: 3453-3464.
15. Tallman MS, Nabhan C. Management of acute promyelo-cytic leukemia. Leukemia 2002; 4: 381-389.
16. Freemantle SJ, Spinella MJ, Dmitrovsky E. Retinoids in cancer therapy and chemoprevention: promise meets resistance. Oncogene 2003; 22: 7305-7315.
17. Mirza N, Fishman M, Fricke I, Dunn M, Neuger AM, Frost TJ et al. All-trans-retinoic acid improves differentiation of myeloid cells and immune response in cancer patients. Cancer Res 2006; 66: 9299-9307.
18. Ades L, Chevret S, Raffoux E, de Botton S, Guerci A, Pigneux A et al. Is cytarabine useful in the treatment of acute promyelocytic leukemia? J Clin Oncol 2006; 24: 5703-5710.
19. Boorjian SA, Milowsky MI, Kaplan J, Albert M, Cobham MV, Coll DM et al. Phase 1/2 clinical trial of interferon a2b and weekly liposome-encapsulated all-trans retinoic acid in patients with advanced renal cell carcinoma. J Immunother 2007; 30: 655-662.
20. Soriano AO, Yang H, Faderl S, Estrov Z, Giles F, Ravandi F et al. Safety and clinical activity of the combination of 5-azacytidine, valproic acid, and all-trans retinoic acid in acute myeloid leukemia and myelodysplastic syndrome. Blood 2007; 110: 2302-2308.
21. Montesinos P, Bergua JM, Vellenga E, Rayon C, Parody R, de la Serna J et al. Differentiation syndrome in patients with acute promyelocytic leukemia treated with all-trans retinoic acid and anthracycline chemotherapy: characteristics, outcome, and prognostic factors. Blood 2009; 113: 775-783.
22. Soprano DR, Qin P, Soprano KJ. Retinoic acid receptors and cancers. Annu Rev Nutr 2004; 24: 201-221.
23. Manna SK, Aggarwal BB. All-trans-retinoic acid upregulates TNF receptors and potentiates TNF-induced activation of nuclear factors-kB, activated protein-1 and apoptosis in human lung cancer cells. Oncogene 2000; 19: 2110-2119.
24. Datta PK, Lianos EA. Retinoic acids inhibit inducible nitric oxide synthase expression in mesangial cells. Kidney Int 1999; 56: 486-493.
25. 2 release from mouse peritoneal macrophages and TNF - a release from rat peripheral blood mononuclear cells. Toxicol Lett 2004; 150: 191-201.
26. Motomura K, Sakai H, Isobe H, Nawata H. All-trans retinoic acid suppresses liver injury induced by propionibac-terium acnes and lipopolysaccharide in rats. J Gastrol Hepatol Commun 1997; 12: 887-892.
27. Oseto S, Moriyama T, Kawada N, Nagatoya K, Takeji M, Ando A et al. Therapeutic effect of all-trans retinoic acid on rats with anti-GBM antibody glomerulonephritis. Kidney Int 2003; 64: 1241-1252.
28. Charoensit P, Kawakami S, Higuchi Y, Hashida M. Incorporation of all-trans retinoic acid into lipoplexes inhibits nuclear factor kB activation mediated liver injury induced by lipoplexes in mice. J Gene Med 2008; 10: 61-69.
29. Nishikawa M, Hyoudou K, Kobayashi Y, Umeyama Y, Takakura Y, Hashida M. Inhibition of metastatic tumor growth by targeted delivery of antioxidant enzymes. J Control Release 2005; 109: 101-107.
30. Kuramoto Y, Nishikawa M, Hyoudou K, Yamashita F, Hashida M. Inhibition of peritoneal dissemination of tumor cells by single dosing of phosphodiester CpG oligonucleo-tide/cationic liposome complex. J Control Release 2006; 10: 226-333.
31. Hyoudou K, Nishikawa M, Umeyama Y, Kobayashi Y, Yamashita F, Hashida M. Inhibition of metastatic tumor growth in mouse lung by repeated administration of polyethylene glycol-conjugated catalase: quantitative analysis with firefly luciferase-expressing melanoma cells. Clin Cancer Res 2004; 10: 7685-7691.
32. Suzuki S, Kawakami S, Chansri N, Yamashita F, Hashida M. Inhibition of pulmonary metastasis in mice by all-trans retinoic acid incorporated in cationic liposomes. J Control Release 2006; 116: 58-63.
33. Kawakami S, Suzuki S, Yamashita F, Hashida M. Induction of apoptosis in A549 human lung cancer cells by all-trans retinoic acid incorporated in DOTAP/cholesterol liposomes. J Control Release 2006; 110: 514-521.
34. Wang H, Xu DX, Lu JW, Zhao L, Zhang C, Wei W. N-acetylcysteine attenuates lipopolysaccharide-induced apoptotic liver damage in D-galactosamine-sensitized mice. Acta Pharmacol Sin 2007; 28: 1803-1809.
35. Mahato RI, Kawabata K, Nomura T, Takakura Y, Hashida M. Physicochemical and pharmacokinetic characteristics of plasmid DNA/cationic liposome complexes. J Pharm Sci 1995; 84: 1267-1271.
36. 33P]DNA following intravenous administration of DNA/cationic lipid complexes in mice: use of a novel radionuclide approach. J Pharm Sci 1996; 85: 612-618.
37. Agresti C, Bernardo A, Del Russo N, Marziali G, Battistini A, Aloisi F et al. Synergistic stimulation of MHC class I and IRF-1 gene expression by IFN-g and TNF - a in oligoden-drocytes. Eur J Neurosci 1998; 10: 2975-2983.
38. Berger AC, Alexander HR, Wu PC, Tang G, Gnant MF, Mixon A et al. Tumour necrosis factor receptor I (p55) is upregulated on endothelial cells by exposure to the tumour-derived cytokine endothelial monocyte-activating polypep-tide II (EMAP-II). Cytokine 2000; 12: 992-1000.
39. Zhou J, Zhang M, Atherton SS. Tumor necrosis factor-alpha-induced apoptosis in murine cytomegalovirus retinitis. Invest Ophthalmol Vis Sci 2007; 48: 1691-1700.
40. Car BD, Eng VM, Schnyder B, LeHir M, Shakhov AN, Woerly G et al. Role of interferon-g in interleukin 12-induced pathology in mice. Am J Pathol 1995; 147: 1693-1707.
41. Motomura K, Isobe H, Sakai H, Nawata H. Suppressive effects of all-trans retinoic acid on the lipopolysaccharide-stimulated release of tumor necrosis factor - a and nitric oxide by rat Kupffer cells in vitro. Int Hepatol Commun 1996; 5: 177-183.